Helping Ensure Day 1 Readiness for Launch of Innovative Anti-Psychotic Therapy

An emerging life science manufacturer was planning to launch a novel, oral based therapy, targeting a population of 2.4 million patients in the highly-genericized and competitive CNS/anti-psychotic market. To bring its therapy to market, they would need to contract with both Medicaid and Medicare programs as well as enter into complex contracts with wholesalers and group purchasing organizations (GPOs).

Learn how IntegriChain helped. Download below!